Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-hodgkin lymphoma

Keyphrases

• Acceptable Safety 100%
• Safety Profile 100%
• Durable Response 100%
• Complete Remission 100%
• Bendamustine 100%
• Rituximab-refractory 100%
• Indolent non-Hodgkin Lymphoma 100%
• Overall Response Rate 75%
• Duration of Response 50%
• Alkylator 50%
• Histology 25%
• United States 25%
• Progression-free Survival 25%
• North America 25%
• Squamous Cell Carcinoma (SqCC) 25%
• Chemotherapy 25%
• Acute Myeloid Leukemia 25%
• Myelodysplastic Syndrome 25%
• Previously Treated 25%
• Lymphoma 25%
• Marginal Zone 25%
• Alkylating Agents 25%
• Long-term Safety 25%
• Similarity Design 25%
• Relapsed Disease 25%
• Previous Chemotherapy 25%
• Design Criteria 25%
• Chemotherapy Regimen 25%
• Lymphoplasmacytic 25%
• Chronic Myeloid Leukemia 25%
• Enrollment Criteria 25%
• Durability of Response 25%
• Refractory Patients 25%
• Novel Mechanism of Action 25%
• Opportunistic Infections 25%
• Mechlorethamine 25%
• Response Criteria 25%
• Indolent Lymphoma 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Remission 100%
• Nonhodgkin Lymphoma 100%
• Rituximab 100%
• Bendamustine 100%
• Disease 25%
• Progression Free Survival 25%
• Chemotherapy 25%
• Squamous Cell Carcinoma 25%
• Patient History of Chemotherapy 25%
• Alkylating Agent 25%
• Acute Myeloid Leukemia 25%
• Nitrogen Mustard 25%
• Chemotherapy Regimens 25%
• Opportunistic Infection 25%
• Myelodysplastic Syndrome 25%
• Chronic Myelomonocytic Leukemia 25%